Posts tagged with "cardiovascular"

Toilet Seat Detects Congestive Heart Failure

Toilet seat that detects congestive heart failure getting ready to begin commercialization

Researchers developed the seats to measure biometrics during ‘natural’ processes

With 1 million new cases of congestive heart failure diagnosed each year, a revolutionary product is making it easier for hospitals to monitor patients with the condition in the comfort of their own homes.

A toilet-seat based cardiovascular monitoring system created by a team of Rochester Institute of Technology researchers, aims to lower the hospital readmission rates of patients with congestive heart failure. The toilet seats, which will be brought through the FDA clearance process by the researchers’ company Heart Health Intelligence, would be purchased by hospitals and issued to heart failure patients after discharge. The toilet seats are equipped to measure the electrical and mechanical activity of the heart, and can monitor heart rate, blood pressure, blood oxygenation levels, and the patient’s weight and stroke volume, which is the amount of blood pumped out of the heart at every beat. Algorithms analyze the data, and with further development, will alert advanced practice providers of a deteriorating condition. A report will be passed along to cardiologists who will then determine if intervention is necessary.

Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, is part of the university team that developed the toilet seats.

“Typically, within 30 days of hospital discharge, 25 percent of patients with congestive heart failure are readmitted,” said Conn. “After 90 days of hospital discharge, 45 percent of patients are readmitted. And the Centers for Medicare and Medicaid Services is penalizing hospitals for readmitting patients for heart failure.”

Conn, the company’s chief executive officer, further explains that using the national average for readmission rates, the penalty alone for readmitting 150 patients is approximately $500,000 annually. The total cost of providing 150 patients with their own monitored toilet seats from HHI is $200,000. With that investment, he says, hospital systems will save more than double their initial investment within one year.

According to Conn, who earned three degrees from RIT—a bachelor’s degree and a master’s degree in electrical engineering in 2011 and 2013, respectively, and a doctoral degree in microsystems engineering in 2016—the system will pick up deteriorating conditions before the patients even realize they are symptomatic. And with the rapid data analysis, interventions can be as simple as a drug change or short office visit, instead of an admission to the hospital.

HHI, which joined RIT’s Venture Creations business incubator earlier this year, is now focused on moving the product forward. The team is heavily involved in writing grants for additional funding and networking, and human-subject testing and pre-clinical studies are well underway. Conn and his team are working on approving the product with the FDA and rolling it out across the country.

To read more about the research behind the project, go to here.

For more information, contact Vienna McGrain at 585-475-4952 or Vienna.Carvalho@rit.edu.

About Rochester Institute of Technology

Rochester Institute of Technology is home to leading creators, entrepreneurs, innovators and researchers. Founded in 1829, RIT enrolls about 19,000 students in more than 200 career-oriented and professional programs, making it among the largest private universities in the U.S.

The university is internationally recognized and ranked for academic leadership in business, computing, engineering, imaging science, liberal arts, sustainability, and fine and applied arts. RIT also offers unparalleled support services for deaf and hard-of-hearing students. The cooperative education program is one of the oldest and largest in the nation. Global partnerships include campuses in China, Croatia, Dubai and Kosovo. To follow RIT on social media, go to www.rit.edu/socialmedia.

Getting to the Heart of the Problem

Although it is well known that cardiovascular disease is the leading cause of death and disability among all Americans, there is still a misconception that it primarily affects older, white men.

The truth is, the risks are even higher for African Americans. African Americans have higher rates of heart disease risk factors such as hypertension, obesity and diabetes. Currently, 44% of African American men and 48% of African American women have some form of heart disease in the U.S.

Experts say there are several reasons why heart disease disproportionally affects the black community ranging from genetic to environmental factors. There are simple ways to control certain risk factors to reduce your risk for heart disease – it can be as simple as changing your daily habits.

Lifestyle Changes Can Include:
-Healthy diet
-Be physically active every day
-Reduce stress
-Quit smoking

During Heart Health Month, Dr. Wayne Batchelor, an interventional cardiologist and member of the Association of Black Cardiologists, is available to explain what you need to know if you have a risk factor that’s out of your control, how to talk to your doctor and the latest advancements in treatment options.

NasalGuard®

A Topical Gel that Reduces Inhalation of Harmful Airborne Contaminants Makes National Debut

Perfect for Flu and Cough Cold Season, Indoor Pollutants, Pet Allergies and More

Trutek Corp. announces the launch of NasalGuard®Airborne Particle Blocker®. NasalGuard is an electrostatic topical nasal gel that prevents airborne particles from entering the nose. The product is drug-free and safe for pregnant or nursing women, children, and those concerned about potential drug interactions with other medications. It is a perfect solution to guard you against the Flu/Cough/Cold and all indoor pollutants this winter season.

NasalGuard protects against virtually all types of contaminants in any location. Users can count on it to work in their homes, offices, and other environments where airborne particles may present a health hazard. The product works immediately upon application and lasts up to six hours. NasalGuard gel uses a cationic (positively-charged) polymer that creates a safe electrostatic field around the nasal passages that traps oppositely charged particles and repels similarly charged particles to reduce inhalation of most harmful airborne particles before they enter your body. NasalGuard gel can be purchased online, Amazon or by calling 855-627-2545 in a 3 gram tube for $11.85.

Every day, people are exposed to millions of airborne particles in crowded, confined spaces such as airports, airplanes, transportation centers and subways, homes and offices, hospitals, doctor’s offices and movie theaters. Using NasalGuard gel regularly will help protect against the immediate and long-term risk of breathing harmful contaminated air.

There has been a growing public health concern globally regarding the adverse health effects caused by the inhalation of microscopic airborne particles. Asthma, diabetes, lung cancer and cardiovascular disease are all proven to be linked to air contamination. In response to this widespread problem, Trutek has successfully advanced their technology which was originally focused on blocking allergens from entering the nose for preventing allergy symptoms. This breakthrough provides a greater electrostatic blocking effect that is effective against a much wider spectrum of microscopic indoor and outdoor contaminants including mold, pollen, pet dander, pollution, and virus-sized particles.

NasalGuard technology was invented by Ashok Wahi, the founder and CEO of Trutek Corp., an R&D Product Development Company. An engineer by training, Ashok was inspired to create this technology to aid his own daughter, Aikta, who suffered from severe allergies. “I developed this product because of the vital need to have some kind of personal air filter that was drug free and easy to use,” says Ashok Wahi.

About Trutek Corp.

Trutek Corp. has been marketing patented NasalGuard technology all over the world since 1995. Over 12 million tubes have been sold with no reports of adverse effects.

Follow us on Facebook @nasalguard